Investors sold shares of Exelixis, Inc. (NASDAQ:EXEL) on strength during trading hours on Wednesday after Oppenheimer lowered their price target on the stock from $40.00 to $31.00. $46.67 million flowed into the stock on the tick-up and $65.99 million flowed out of the stock on the tick-down, for a money net flow of $19.32 million out of the stock. Of all stocks tracked, Exelixis had the 0th highest net out-flow for the day. Exelixis traded up $0.37 for the day and closed at $22.05
EXEL has been the topic of several other reports. BidaskClub raised shares of Exelixis from a “sell” rating to a “hold” rating in a research note on Saturday, December 1st. ValuEngine downgraded shares of Exelixis from a “hold” rating to a “sell” rating in a research note on Saturday, January 19th. Zacks Investment Research downgraded shares of Exelixis from a “buy” rating to a “hold” rating in a research note on Monday. TheStreet raised shares of Exelixis from a “c+” rating to a “b-” rating in a research note on Monday, December 17th. Finally, Piper Jaffray Companies decreased their price target on shares of Exelixis from $29.00 to $26.00 and set an “overweight” rating on the stock in a research note on Monday, November 5th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $27.25.
In other Exelixis news, EVP Jeffrey Hessekiel sold 11,759 shares of Exelixis stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $19.12, for a total transaction of $224,832.08. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director George A. Scangos sold 40,000 shares of Exelixis stock in a transaction dated Friday, February 1st. The stock was sold at an average price of $23.53, for a total transaction of $941,200.00. Following the transaction, the director now directly owns 1,363,031 shares in the company, valued at $32,072,119.43. The disclosure for this sale can be found here. Insiders have sold 337,807 shares of company stock worth $7,248,232 over the last ninety days. 4.80% of the stock is owned by insiders.
The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.54 and a current ratio of 8.66. The company has a market capitalization of $6.44 billion, a P/E ratio of 43.24, a PEG ratio of 1.34 and a beta of 2.21.
Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 12th. The biotechnology company reported $0.37 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.14. Exelixis had a net margin of 49.53% and a return on equity of 55.71%. The company had revenue of $228.60 million for the quarter, compared to the consensus estimate of $188.44 million. During the same period in the previous year, the firm earned $0.12 earnings per share. Exelixis’s quarterly revenue was up 90.4% compared to the same quarter last year. On average, analysts predict that Exelixis, Inc. will post 1.3 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2019/02/14/investors-sell-exelixis-exel-on-strength-on-analyst-downgrade.html.
About Exelixis (NASDAQ:EXEL)
Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
See Also: Do Tariffs Work?
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.